Literature DB >> 22064630

Does VSL#3 really improve symptoms in children with IBS?

Robert J Shulman, E O'Brian Smith.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22064630      PMCID： PMC4419702          DOI： 10.1097/MPG.0b013e31823df69b

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  8 in total

1.  VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study.

Authors:  Stefano Guandalini; Giuseppe Magazzù; Andrea Chiaro; Valeria La Balestra; Giovanni Di Nardo; Sarath Gopalan; A Sibal; Claudio Romano; Roberto Berni Canani; Paolo Lionetti; Mala Setty
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-07       Impact factor: 2.839

2.  Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea.

Authors:  P Brigidi; B Vitali; E Swennen; G Bazzocchi; D Matteuzzi
Journal:  Res Microbiol       Date:  2001-10       Impact factor: 3.992

3.  Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.

Authors:  Liam O'Mahony; Jane McCarthy; Peter Kelly; George Hurley; Fangyi Luo; Kersang Chen; Gerald C O'Sullivan; Barry Kiely; J Kevin Collins; Fergus Shanahan; Eamonn M M Quigley
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

4.  Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.

Authors:  S Guglielmetti; D Mora; M Gschwender; K Popp
Journal:  Aliment Pharmacol Ther       Date:  2011-03-21       Impact factor: 8.171

Review 5.  Design of treatment trials for functional gastrointestinal disorders.

Authors:  E Jan Irvine; William E Whitehead; William D Chey; Kei Matsueda; Michael Shaw; Nicholas J Talley; Sander J O Veldhuyzen van Zanten
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

6.  Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

Authors:  A Venturi; P Gionchetti; F Rizzello; R Johansson; E Zucconi; P Brigidi; D Matteuzzi; M Campieri
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

7.  Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.

Authors:  E A Williams; J Stimpson; D Wang; S Plummer; I Garaiova; M E Barker; B M Corfe
Journal:  Aliment Pharmacol Ther       Date:  2008-09-09       Impact factor: 8.171

8.  Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota.

Authors:  K Kajander; E Myllyluoma; M Rajilić-Stojanović; S Kyrönpalo; M Rasmussen; S Järvenpää; E G Zoetendal; W M de Vos; H Vapaatalo; R Korpela
Journal:  Aliment Pharmacol Ther       Date:  2007-10-05       Impact factor: 8.171
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.